Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Switching approach in the management of schizophrenia patients
Autore:
Peuskens, J;
Indirizzi:
Univ Ctr St Jozef Kortenberg, Louvain, Belgium Univ Ctr St Jozef Kortenberg Louvain Belgium rtenberg, Louvain, Belgium
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
, volume: 15, anno: 2000, supplemento:, 4
pagine: S15 - S19
SICI:
0268-1315(200012)15:<S15:SAITMO>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC WITHDRAWAL; ANTIPSYCHOTIC MEDICATIONS; DISCONTINUATION; DYSKINESIA; DRUGS; PSYCHOPATHOLOGY; GUIDELINES; SYMPTOMS;
Keywords:
amisulpride; clozapine; risperidone; olanzapine; quetiapine; ziprasidone; zotepine; compliance; quality of life; refractory; positive symptoms; negative symptoms; depressive symptoms; withdrawal; relapse; drug interactions; education; weight gain;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Peuskens, J Univ Ctr St Jozef, Leuvensesteenweg 517, B-3070 Kortenberg, Belgium Univ Ctr St Jozef Leuvensesteenweg 517 Kortenberg Belgium B-3070
Citazione:
J. Peuskens, "Switching approach in the management of schizophrenia patients", INT CLIN PS, 15, 2000, pp. S15-S19

Abstract

Atypical neuroleptics combine efficacy with good tolerability. As a result, prognosis and quality of life may improve when patients receiving treatment with traditional agents are switched to an atypical compound. Major indications for switching are lack of or incomplete response to classical neuroleptic treatment, and/or the occurrence of extrapyramidal symptoms. The previous treatment should be discontinued, preferably progressively, and the new one started, overlapping the previous treatment. Caution is advised in patients who have suffered a recent relapse, a severe psychotic episode or who are being treated as outpatients. Anticholinergic medication, if needed,should be continued for 2-4 weeks after the switch has been made. The physician should be aware of the potential drug interactions leading to increased sedation or hypotension. Patient education is vital when switching medications. Treatment should be individualized. Patients who have gained weighton previous therapy, or who have negative symptoms of schizophrenia and depressive symptoms, are particularly likely to benefit from amisulpride. Furthermore, the highly selective affinity of amisulpride for dopaminergic receptors with its lack of interference with other neurotransmitter systems facilitates the change in treatment. mt clin Psychopharmacol 2000, 15 (suppl 4):S15-S19 (C) Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 10:29:46